Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients receiving letrozole or letrozole plus bevacizumab: CALGB 40503 (Alliance)
- Citation:
- J Clin Oncol vol 37 (15_suppl) 1049-1049
- Meeting Instance:
- ASCO 2019
- Year:
- 2019
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3318
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Mark Jesus M. Magbanua Oleksandr Savenkov Erik J. Asmus Karla V. Ballman Janet H. Scott John W. Park Maura Dickler Ann Partridge Lisa Carey Eric Winer Hope S. Rugo
- Networks:
- AURORA, CA136, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: